These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27493690)

  • 1. Intravenous zoledronate for osteoporosis: less might be more.
    Grey A
    Ther Adv Musculoskelet Dis; 2016 Aug; 8(4):119-23. PubMed ID: 27493690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Jul; 3(7):1007-9. PubMed ID: 12083999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.
    Grey A; Bolland MJ; Wattie D; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2009 Feb; 94(2):538-44. PubMed ID: 19050050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute delirium in an elderly woman following zoledronate administration.
    Nasiruddin M; Fayazuddin M; Zahid M; Iftekhar S
    J Pharmacol Pharmacother; 2014 Jul; 5(3):217-9. PubMed ID: 25210406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis.
    Saraff V; Sahota J; Crabtree N; Sakka S; Shaw NJ; Högler W
    Arch Dis Child; 2018 Jan; 103(1):92-94. PubMed ID: 28988216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
    Grey A; Bolland M; Wattie D; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2010 Oct; 25(10):2251-5. PubMed ID: 20499349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
    Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
    Hagino H; Hashimoto J; Okano T; Katagiri H
    Clin Calcium; 2008 Aug; 18(8):1176-82. PubMed ID: 18677057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
    HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
    Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronate Therapy for the Pathological Humeral Fracture in Polyostotic Fibrous Dysplasia: A Case Report.
    Ohno I; Higuchi C
    J Clin Med Res; 2015 Nov; 7(11):901-6. PubMed ID: 26491505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.
    Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
    J Intern Med; 2019 Aug; 286(2):221-229. PubMed ID: 30887607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of acute anterior uveitis after intravenous zoledronate.
    Patel DV; Horne A; House M; Reid IR; McGhee CN
    Ophthalmology; 2013 Apr; 120(4):773-6. PubMed ID: 23290982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.